567 results about "Smooth muscle" patented technology

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention discloses a bionic nano-composite, a preparation method thereof and application of the bionic nano-composite in preparation of a product for treating atherosclerosis, and belongs to the technical field of medicine preparation. The bionic nano compound is a metal nano enzyme Ir-TiO2 coated by an M2 macrophage cell membrane. According to the invention, the surfaces of Ir-TiO2 nanoparticles are coated with M2 macrophage membranes, so that the nanocomposite with a bionic structure is prepared. After intravenous injection, the formed bionic nanocomposite can actively target endothelial cells in atherosclerotic lesions, and release Ir-TiO2 antagonism to endothelial cells in plaques and cytoplasm of inflammatory macrophages. After the Ir-TiO2 reaches the diseased region, the Ir-TiO2 can play an enzyme role to achieve an anti-inflammatory effect, and can promote inflammatory cells such as macrophages and smooth muscle cells at the diseased region to discharge cholesterol, reduce lipid deposition in the cells, reduce the generation of foam cells and promote the growth of plaques. The nanotherapy can effectively prevent the progress of atherosclerosis lesion inflammation and relieve atherosclerosis.

The invention discloses a stem cell exosome based on targeted fusion polypeptide modification, a preparation method and application of the stem cell exosome in treating male erectile dysfunction. According to the exosome, a specific targeting fusion polypeptide (sequence: EPLQLKM-GGGS-DPPV) is anchored on the surface through a chemical coupling technology, so that the targeting property of the exosome on cavernosum smooth muscle cells is enhanced; meanwhile, an anti-TrkA monoclonal antibody (TrkA-2E7-HL) is loaded through an electroporation method, and a fibrosis pathway mediated by a nerve growth factor (NGF) is inhibited. The exosome induces secretion of the umbilical cord mesenchymal stem cells by adopting an anti-oxidation culture medium, so that the anti-oxidation activity of the exosome is remarkably improved. Experiments show that in a diabetes ED rat model, the erectile function (ICP / MAP ratio) of the modified exosome is improved to 0.79 + / -0.05, the fibrosis area is reduced to 9.2 + / -1.6%, and the NO secretion level is improved by 3.5 times compared with that of a common exosome. Through triple mechanisms of polypeptide targeting, antibody synergy and oxidation resistance, effective reversion of the ED pathological process is realized, and the polypeptide has remarkable novelty and clinical transformation potential.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, those within the respiratory tract, particularly the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The systems may be used to treat pathogens, such as bacteria and viruses, particularly coronaviruses.

The invention discloses a preparation method and application of a response type NO release anticoagulant hydrogel material. The preparation method comprises the following steps: providing methylacryloylated recombinant collagen; providing methacrylated hyaluronic acid; providing caffeic acid arginine amide modified hyaluronic acid; the response type NO release anticoagulant hydrogel material is obtained by taking methylacryloylated recombinant collagen, methylacryloylated hyaluronic acid and caffeic acid arginine amide modified hyaluronic acid as raw materials. The prepared hydrogel material has the advantages of resisting bacteria, promoting proliferation of endothelial cells, inhibiting proliferation of smooth muscle cells, resisting inflammation, promoting angiogenesis, inhibiting thrombosis and the like, arginine can serve as an endogenous NO donor in blood to release NO molecules, and therefore the effect of promoting vascular endothelial repair is achieved, and the hydrogel material has the advantages of being capable of resisting bacteria, promoting proliferation of endothelial cells, inhibiting proliferation of smooth muscle cells, resisting inflammation, promoting angiogenesis, inhibiting thrombosis and the like. The introduced NO molecules enable the hydrogel material to have good anticoagulant performance, and the hydrogel material is expected to be used for preparing an artificial blood vessel anticoagulant coating.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention discloses application of decitabine in preparation of a medicine for resisting vascular calcification, and belongs to the technical field of medical biology. A CKD mouse vascular calcification model is constructed through combination of 5 / 6 nephrectomy and high phosphorus diet (5 / 6NX), and it is observed that the expression level of DNMT3A in model mouse calcified blood vessels is remarkably increased, and the DNA methylation degree is remarkably increased. Based on this, people try to use decitabine to reduce the expression of DNMT, and discover that intraperitoneal injection of decitabine inhibits the expression of DNMT3A in CKD artery blood vessels and osteogenesis-like transdifferentiation of vascular smooth muscle cells, so that CKD-related vascular calcification is effectively relieved.

Apparatus and methods for deactivating bronchial nerves and ablating smooth muscle extending along a bronchial branch of a mammalian subject to treat asthma and related conditions. An ultrasonic transducer (11) is inserted into the bronchus as, for example, by advancing the distal end of a catheter (10) bearing the transducer into the bronchial section to be treated. The ultrasonic transducer emits ultrasound so as to heat tissues throughout a relatively large impact volume (13) to a temperature sufficient to inactivate nerve conduction and ablate smooth muscle but insufficient to cause rapid ablation or necrosis of the surrounding tissues. The treatment can be performed without locating or focusing on individual bronchial nerves or smooth muscle.

The invention relates to an application of a histone H3K18 lactic acid modification related target in preparation of a medicine for preventing or treating atherosclerosis. The invention belongs to the field of biological medicine, and discloses histone acetyltransferase P300 and application of histone H3K18 lactylation (H3K18la) modification mediated by the histone acetyltransferase P300 as a new target spot for treating atherosclerosis (AS). Researches find that in the AS process, lactic acid accumulation in vascular smooth muscle cells (VSMCs) up-regulates H3K18la through P300 catalysis, and then the pathological phenotype of the VSMCs is induced, and plaque development is promoted. H3K18la can be reduced and the phenotype can be improved by inhibiting LDHA and MCT1 in vitro or knocking out a P300 gene; the P300 for in-vivo targeted inhibition of the VSMCs can significantly reduce the artery plaque. Therefore, the P300 and H3K18la inhibitors can be used for preparing the anti-atherosclerosis medicine.

Provided herein are optionally substituted pyrazolylacetamides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating diseases or disorders, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania, tinnitus, neurodevelopmental diseases or disorders, a smooth muscle contractility disorder, Dravet syndrome, posttraumatic stress disorder (PTSD), with such compounds and pharmaceutical compositions.

The invention discloses shRNA (short hairpin Ribonucleic Acid) for targeted knockout of an Eif2ak2 gene and application, and belongs to the technical field of gene engineering. The shRNA comprises a positive-sense strand and an antisense strand which is reversely complementary with the positive-sense strand, and the nucleotide sequence of the positive-sense strand is shown as SEQ ID NO. 5. It is found for the first time that the recombinant adeno-associated virus capable of inhibiting Eif2ak2 gene expression can successfully inhibit the phenotype of the abdominal aortic aneurysm of a mouse, obviously reduce the morbidity of the abdominal aortic aneurysm of the mouse, improve the severity of the abdominal aortic aneurysm of the mouse, reduce the inner diameter of a blood vessel and the ratio of the weight to the body weight of the blood vessel, and promote the contraction function of vascular smooth muscle cells of the mouse; the method can be used for effectively treating the abdominal aortic aneurysm, provides a new thought and strategy for treating the abdominal aortic aneurysm, and has a wide clinical application prospect.

The present invention relates to methods for obtaining induced smooth muscle cells (iSMCs), iSMCs, iSMCs for use in a method of treating a disease or disorder or for use in tissue engineering, and the use of skeletal muscle derived cells for obtaining iSMCs.

The invention belongs to the field of biological medicine, and particularly relates to application of deaminotyrosine in preparation of a medicine for treating vascular calcification symptoms. The invention finds that deaminotyrosine can significantly reduce the vascular calcification degree of an in-vitro cell model and an in-vivo animal model by inhibiting osteogenic differentiation and calcium salt deposition of vascular smooth muscle cells; therefore, the invention provides a new application of the deaminated tyrosine or pharmaceutically acceptable salt, ester, solvate or prodrug thereof in preparation of drugs for treating vascular calcification symptoms. The invention also provides a pharmaceutical composition, which takes deaminated tyrosine as an active component, and provides a brand new drug choice for clinical prevention and treatment of vascular calcification.

The invention discloses a galiaceae-euphorbia tripsacus compound extract as well as a preparation method and vagina repair application thereof. The compound extract is prepared from galiaceae herbs and euphorbia tripsacus according to a scientific ratio through compound enzymolysis pretreatment, gradient ethanol solvent step-by-step extraction and double-resin series purification. According to the preparation method, the dissolution rate of the active components is remarkably increased by utilizing an enzymolysis wall breaking technology, the problem that the purity of the multi-polar components (tannin, flavone and polysaccharide) is difficult to increase and extract at the same time is solved through gradient extraction and series purification, and the purity of the total active components is more than or equal to 60%. The obtained composite extract has multiple effects of astringing and tightening, promoting regeneration of elastic fibers and improving contractility of smooth muscles, and is safe and non-irritant. The invention further discloses targeted sustained-release gel containing the extract, and the targeted sustained-release gel can be used for improving vaginal relaxation and deeply repairing private parts.

The invention discloses application of salvianolic acid A in preparation of a medicine for preventing and treating vulnerable plaques of advanced atherosclerosis. The invention also discloses application of the salvianolic acid A combined with ferulic acid or the salt thereof in preparation of drugs for preventing and treating advanced atherosclerosis vulnerable plaques. Researches find that salvianolic acid A can promote apoptosis of senescent vascular smooth muscle cells and has a Senlytics effect; the salvianolic acid A stabilizes vulnerable atherosclerotic plaques by reducing the load of senescent vascular smooth muscle cells; the salvianolic acid A is in non-covalent binding with ASP54, ALA55, LYS58, ASP93, ASP102 and LYS112 of the HSP90AA1 to play a role in inhibition, and the ASP93 has the greatest contribution to binding free energy. The research of the invention is of great significance to the development and application of drugs with anti-aging effect for stabilizing advanced atherosclerotic vulnerable plaques.

Provided herein are optionally substituted pyrazolylacetamides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating diseases or disorders, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania, tinnitus, neurodevelopmental diseases or disorders, a smooth muscle contractility disorder, Dravet syndrome, posttraumatic stress disorder (PTSD), with such compounds and pharmaceutical compositions.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus rhamnosus MBP01 capable of relieving constipation and application of the lactobacillus rhamnosus MBP01. The invention discloses an application of lactobacillus rhamnosus in preparation of a product for prevention, treatment and / or adjuvant treatment of constipation. The preservation number of the lactobacillus rhamnosus is GDMCC (China General Microbiological Culture Collection Center) NO: 64725. The lactobacillus rhamnosus relieves mouse constipation caused by icy water activated carbon by adjusting the content of cell factors and the mRNA expression level of constipation-related genes, accelerating secretion of gastric acid and enzymes in pancreas, promoting peristalsis of stomach and gastric acid secretion, accelerating gastrointestinal motility, accelerating contraction of intestinal smooth muscles and inhibiting the activity of inflammatory cells. The lactobacillus rhamnosus has a better prospect in preparation of health-care food with the functions of relieving constipation and promoting digestion and in preparation of medicines for clinically treating constipation.

The invention provides a balloon catheter system which comprises a balloon catheter with a balloon and a restraining support, the outer surface of the balloon is provided with a concave part, the restraining support is arranged outside the balloon and comprises a restraining part, and when the interior of the balloon reaches preset pressure and is in an expansion state, the restraining part is used for restraining the balloon. The restraining part makes contact with the outer surface of the balloon and limits radial expansion of the balloon in the contact area of the restraining part and the outer surface of the balloon, the concave part and the restraining part are matched to form a plurality of protruding parts on the surface of the balloon, the protruding parts can extrude the narrow section of the blood vessel, atheromatous substances, arterial plaques and the like of the narrow section are extruded to deform and attached to the inner wall of the blood vessel, and therefore the blood vessel is protected. And a good blood vessel expansion effect is achieved. Meanwhile, the concave areas are formed among the convex parts, extruded atheromatous substances, artery plaques and the like can move towards the concave areas among the convex parts nearby, part of extruded force is released, and the situation that the blood vessels are damaged due to the fact that smooth muscles of the blood vessel walls are torn too much is avoided.

The invention discloses a functional coating, an intravascular stent and a preparation method and application of the intravascular stent. The functional coating comprises an endothelialization promoting active substance and an anti-proliferation drug; the endothelialization promoting active substance comprises at least one of polypeptide containing an RGD sequence, polypeptide containing a YIGSR sequence, polypeptide containing an REDV sequence, a beta-polypeptide polymer or a beta-polypeptide-polyester block copolymer. The functional coating disclosed by the invention can be used for surface functional modification of interventional medical devices, can selectively promote adhesion and proliferation of vascular endothelial cells at an implantation part, realizes rapid endothelialization, and can controllably release an anti-proliferation drug to inhibit excessive proliferation of vascular smooth muscle cells, so that the vascular endothelial cells are prevented from being damaged. Therefore, the risks of restenosis and advanced thrombus are effectively reduced.

The invention discloses an application of a compound Isaridin E or a pharmaceutical salt thereof in preparation of anti-vascular calcification drugs and related diseases, and relates to the technical field of medical biology. A classical high phosphate induced smooth muscle cell calcification model and an in-vivo vascular calcification model induced by a high dose of vitamin D3 are adopted, and through an in-vitro cell experiment, an in-vitro experiment and an overall animal experiment, it is found that the compound Isaridin E has a remarkable improvement effect on vascular calcification caused by calcium and phosphorus metabolism disorder. The medicine has the effects of remarkably inhibiting vascular smooth muscle cell osteogenic differentiation induced by high phosphate and vitamin D3, inhibiting vascular calcification and remarkably reducing formation of calcium-phosphorus crystals on vascular walls. The invention develops a brand new medical application of the marine compound Isaridin E, and the marine compound Isaridin E can be used for research and development of drugs for treating vascular calcification and calcification-related diseases.

The invention relates to a phenylacetylglutamine / phenylacetylglycine induced vascular smooth muscle cell senescence model and an establishment method and application thereof, and belongs to the technical field of cell models.The method comprises the following steps that vascular smooth muscle cell suspension is placed in a porous plate, 10% of FBS and 1% of mycillin are added into a culture medium, 24 h after cells adhere to the wall, the vascular smooth muscle cell senescence model is obtained, and the vascular smooth muscle cell senescence model is obtained. The method comprises the following steps of: adding a proper amount of phenylacetyl glutamine or phenylacetyl glycine dimethyl sulfoxide solution into a porous plate, changing a serum-free culture medium, continuously culturing for 24 hours, adding a proper amount of phenylacetyl glutamine or phenylacetyl glycine dimethyl sulfoxide solution into the porous plate, changing the culture medium added with phenylacetyl glutamine or phenylacetyl glycine once every 24 hours, and collecting cells after 72 hours. According to the invention, phenylacetylglutamine / phenylacetylglycine is used for inducing and establishing the vascular smooth muscle cell senescence model for the first time, the method is easy to operate and low in cost, and a foundation is laid for researching the relationship between cardiovascular diseases and senescence.

The present invention relates to the technical field of arteriovenous fistulas. Provided is an optimized scheme for postoperative vasodilation of an autologous arteriovenous fistula. The optimized scheme comprises microwave and electromagnetic field stimulation, ultrasonic monitoring and AI analysis, nano-drug sustained-release technology and intelligent pressure regulation. A microwave and electromagnetic field module stimulates vascular smooth muscle by means of precisely controlling a frequency and an intensity; an ultrasound monitoring module collects real-time data on a vascular inner diameter and a blood flow volume; an AI module dynamically adjusts a stimulation intensity on the basis of the data; a nanoparticle sustained-release system realizes long-acting drug release; and a pressure regulation module automatically regulates, by means of a closed-loop control algorithm, external pressure applied to blood vessels. The problems of imprecise physical stimulation, unsustained pharmaceutical support, fixed pressure regulation, etc., in traditional management of postoperative vasodilation are effectively solved.

Provided herein are optionally substituted pyrazolylacetamides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating diseases or disorders, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania, tinnitus, neurodevelopmental diseases or disorders, a smooth muscle contractility disorder, Dravet syndrome, posttraumatic stress disorder (PTSD), with such compounds and pharmaceutical compositions.

The invention discloses an application of 4-octyl itaconic acid (4-OI) in preparation of a medicine for improving pulmonary arterial hypertension (PAH). In-vivo experiments show that 4-OI can significantly reduce pulmonary vascular wall thickening and collagen deposition of a PAH rat model, and effectively improve PAH and vascular remodeling. In-vitro experiments further reveal that 4-OI reduces endoplasmic reticulum stress (ERS) by inhibiting a PERK-eIF2alpha pathway, further blocks SM22 dependent smooth muscle cell phenotypic transformation and endothelial-mesenchymal transformation (EndMT) processes, finally inhibits vascular remodeling, and plays a role in treating PAH. The three key pathological processes of ERS, EndMT and vascular remodeling are closely linked, a new perspective is provided for deeply understanding the correlation among oxidative stress, endothelial dysfunction and vascular structure change in PAH, meanwhile, a theoretical foundation is laid for developing PAH and vascular remodeling accurate treatment drugs, and clinical transformation value is achieved.

The invention discloses a covered stent, which relates to the technical field of interventional medical instruments and comprises a covered stent section and bare stent sections connected to two axial ends of the covered stent section. The covered stent section comprises a stent main body in a pipe network shape and a tubular covering film covering the surface of the stent main body; the bare stent section comprises a bare stent connected to the axial end part of the covered stent section; the bare stent is formed by weaving a first metal wire in a spiral spring shape, and the stent main body is formed by weaving a second metal wire in a spiral spring shape; and the bare stent is loaded with an anti-hyperplasia drug. The bare stents are arranged at the two ends of the covered stent section, the anti-hyperplasia medicine is loaded on the bare stents, the bare stents are formed by weaving the first metal wires in the spiral spring shape, the bare stents can better conform to the inner cavity of a blood vessel, stimulation to the blood vessel is reduced, and therefore hyperplasia of smooth muscle cells of the blood vessel is reduced; the anti-hyperplasia drug can inhibit hyperplasia of vascular smooth muscle cells, and finally the situation that the two ends of the covered stent are narrow is prevented or reduced.

The application provides an active exosome stent coating, a vascular stent and a preparation method and application, and belongs to the technical field of biomedical intervention instruments. The active exosome stent coating of the application adopts stem cell-derived myocardial cell active exosomes which are strengthened by active components of traditional Chinese medicine. Compared with commercial myocardial cells, the stem cell-derived myocardial cells have more significant effects of promoting blood vessels and tissue repair and regeneration, and stronger cytokine secretion capacity. The preparation method of the active exosome stent coating of the application adjusts the introduction sequence and premixing mode of active components such as exosomes and drugs, and enhances the homogeneity and stability. The vascular stent prepared by using the active exosome stent coating of the application has reasonable sequential release kinetics design, can realize precise targeted regulation on human coronary artery smooth muscle cells (HCASMC) in vitro, does not affect the repair potential of endothelial cells, and solves the contradiction between traditional stents in terms of "anti-proliferation and promotion of healing".

The invention discloses a method for detecting the influence of hypoxia on autophagy of rat pulmonary artery smooth muscle cells, and relates to the field of medicine. Comprising the following steps: cell culture: selecting rats in different oxygen states, and separating and culturing pulmonary artery smooth muscle cells through a tissue adherence method; detection: carrying out the following detection on the smooth muscle cells: WB detection of autophagy and ferroptosis related proteins; performing ELISA (enzyme-linked immunosorbent assay) detection on related markers; carrying out qPCR detection on mRNA related to autophagy and ferroptosis; cell autophagy detection; carrying out ROS detection in the cells; and detecting ferrous ions in cells. According to the invention, rat pulmonary artery smooth muscle cells in different oxygen states are respectively subjected to autophagy and ferroptosis related protein detection, related marker detection, autophagy and ferroptosis related mRNA detection, cell autophagy detection, intracellular ROS detection and intracellular ferrous ion detection, so that the influence of autophagy on ferroptosis can be effectively proved; and the blank of medical technology is filled.

The invention belongs to the technical field of medicines, and particularly relates to application of sophora alcohol T in preparation of an anti-hepatic fibrosis medicine. The invention provides the application of the sophora alcohol T in preparation of the anti-hepatic fibrosis medicine for the first time, for example, the sophora alcohol T can be applied to preparation of the medicine for preventing or treating hepatic fibrosis. The compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise, and has good patent medicine potential and wide development, transformation and clinical application value and prospect, and the compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise.

The invention provides application of retinoic acid in preparation of a medicine for treating vascular calcification, and belongs to the technical field of medicines. The early warning and treatment effects of retinoic acid on vascular calcification are provided for the first time, a new source is provided for preparing the medicine for early warning and / or treating vascular calcification, and meanwhile the new medicinal value of retinoic acid is explored. Cardiovascular calcification and vascular smooth muscle cell calcification are relieved by supplementing retinoic acid in vivo and in vitro, and the feasibility that retinoic acid can be used as a potential medicine for treating vascular calcification is prompted. The retinoic acid content is in negative correlation with the coronary artery calcification integral of the human body and the calcification severity degree, and it is prompted that the retinoic acid content can serve as an early warning index of cardiovascular calcification and the severity degree.

The invention relates to the technical field of medicines, and provides a pharmaceutical composition and application thereof. The pharmaceutical composition is prepared from erdosteine, benpipralin phosphate, olopatadine hydrochloride and procaterol hydrochloride. The pharmaceutical composition has the effects of relieving cough, eliminating phlegm and relieving asthma at the same time. Meanwhile, the erdosteine, the benpipralin phosphate, the olopatadine hydrochloride and the procaterol hydrochloride are compounded to achieve a synergistic effect, and the olopatadine hydrochloride is compounded to inhibit inflammatory exudation caused by respiratory tract infection and relax respiratory tract smooth muscles, so that the cough relieving and phlegm eliminating effects of the pharmaceutical composition are effectively improved; the cough relieving effect of the pharmaceutical composition is obviously better than that of benpipralin phosphate, and the phlegm eliminating effect of the pharmaceutical composition is obviously better than that of erdosteine.